Last week we attended ELRIG UK Drug Discovery meeting in ExCeL London, and it was a great pleasure for us to present our poster about neurotoxicity testing using HCS there. Many interesting posters were displayed in the vendor area (see below), allowing exciting scientific discussions between the sessions! We enjoyed Read more…
We are very happy to be highlighted by our partner Molecular Devices in this article : “HCS Pharma uses ImageXpress Micro Confocal Systems for phenotypic screening of physiologically relevant 3D cell models”. We have made a great work together in the conception and building of our platform HAPIx. With the skills Read more…
Next week (the 23th and the 24th of May), we will be in Strasbourg to participate to ELRIGfr event, where we will present two posters. The first poster is about BIOMIMESYS® hydroscaffold for 3D cell culture and the compatibility with automation; the plates can be seeded, treated easily using the VIAFLO 96/384. Read more…
Our CEO will be in Boston from Monday (November 7) to Wednesday (November 9).
The leading lights in drug discovery research across pharma, biotech, academia and the vendor community !
Curious about our toxicology and phenotypic screening services ?
Poster – In vitro dermocosmetology : high content analysis approach using human primary keratinocytes and fibroblasts
Cell biology is part of the R&D activity in dermocosmetology, as providers of active extracts or pure compounds have to demonstrate their efficacy and safety. At HCS Pharma, we are developing new dermocosmetology assays on relevant cellular models, like human primary keratinocytes and human primary fibroblasts, using our automated platform and high content analysis system.
All these emerging technologies and data analysis systems promise interesting discoveries in the near future.
Méryl Roudaut* will present a poster on the work of Institut du Thorax
During ELRIGfr event in Rennes, We had the opportunity to present our work on genotoxicity assay (comet assay on TK6 & gH2AX on keratinocytes and HepG2) in collaboration with the team of in vitro of Galderma R&D. It is really exciting to work with them since they are really experts Read more…
Cell-based high-content screening (HCS) assays have become an increasingly attractive alternative to traditional in vitro and in vivo testing in pharmaceutical drug development and toxicological safety assessment.
Manufacturers have developed super-corrected optics that allow co-localization studies with much more accuracy than before
« Phenotypic Drug Discovery with High Content Screening » by Permin Elmer
I was present at the last congress ELRIGfr in Brussels. It was a strong exchange place with interesting presentations around robotics. It is always really interesting to see examples of innovative automation which give really robust results.
Poster – High Content Screening of automated wound healing and cytotoxicity assays in 2D and 3D culture
To find anti-cancer drugs, different cellular modifications can be looked at: cell death effect on proliferating cells either in 2D culture or on spheroids (3D culture), anti-mitotic, anti-migration/invasion, anti-angiogenesis effects… Different assays can be performed to follow these different effects. High content screening is a multi-parametric technology allowing searching for poly-effects drugs.
The data analysis and statistics, especially the Z-score that everybody knows, need to be reviewed. Guyon et al boast Φ-score.
In this article, authors emphasize the importance of standardisation in the development of HCS.